Abstract 5222
Background
Targeted hotspot cancer NGS panels are becoming an integral part of clinical practice for detection of clinically relevant mutations. Tumor mutation burden (TMB) has arisen as a biomarker in the immunotherapy field, challenging established hotspot panels. So far, testing has been steep, limited to whole exome sequencing (WES) or external commercial NGS assays, neither of which are feasible strategies for future local testing. Clinical routine implementation requires development and validation of new, comprehensive tests, able to deal with day-to-day reality in testing labs, such as input DNA quality and amount limitations or turnaround-time restraints.
Methods
We designed a custom NGS assay, VHIO-300, to detect mutations, copy number alterations (CNA), gene fusions, loss-of-heterozygosity and TMB scoring from tumor samples. VHIO-300 is a capture enrichment of over 430 cancer genes, covering enough sequence to allow TMB calculation (≈1.3 Mb), as well as 2 Mb of non-coding genomic regions. Here, we report the analytical and clinical validation procedures. Analytical sensitivity was conducted on positive control DNAs derived from 5 ATCC cell lines comprising 40 SNVs and indels. Clinical samples with WES data were used to determine specificity, sensitivity and robustness. VHIO-300 performance for TMB calling was tested using 50 FFPE-derived tumor specimens compared to scores provided from both WES and Foundation One test.
Results
Panel design was tuned to improve detection of capture-sensitive variants such as indels, that affect relevant genes in cancer like EGFR, BRCA1/2 or KIT, improving analytical sensitivity by two-fold. The VHIO-300 panel achieved 92.5% clinical sensitivity and 99.9% clinical specificity for SNVs and indel calling compared to WES data. CNA achieved 85% sensitivity and 99.6% specificity compared to array comparative genomic hybridization. Several in-silico TMB calculation algorithms were tested with WES data, the most accurate included both synonymous and non-synonymous calls (r2=0.94).
Conclusions
We provide a complete analytical validation of VHIO-300 panel that makes it a convenient choice for clinical laboratories where a comprehensive genome profiling of FFPE tumor samples is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d’Hebron Institute of Oncology.
Funding
Bristol-Meyers Squibb.
Disclosure
A. Oaknin: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Inmunogen ; Advisory / Consultancy: Genmab ; Travel / Accommodation / Expenses: Roche. M. Alsina Maqueda: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Servier; Research grant / Funding (institution): Merck. J. Capdevila: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Ipsen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merk; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen. E. Elez Fernández: Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Roche; Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (self): Merck Sorono; Honoraria (self), Research grant / Funding (self): Sanofi. T. Macarulla Mercade: Advisory / Consultancy: Roche; Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier. J. Carles: Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Johnson & Johnson ; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas Pharma; Advisory / Consultancy: AstraZeneca. C. Saura: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Puma; Advisory / Consultancy: Sanofi. J.A. Rodon: Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche Pharmaceuticals ; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Orion Pharmaceuticals; Advisory / Consultancy: Servier Pharmaceuticals; Advisory / Consultancy: Peptomyc. R. Dienstmann: Advisory / Consultancy: Roche; Research grant / Funding (self): merck. P.G. Nuciforo: Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: MSD. E. Garralda: Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Leadership role: ESMO Women for Oncology; Non-remunerated activity/ies: ESMO. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KGaA; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche. J. Tabernero: Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Chugai; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Novartis; Advisory / Consultancy: Hoffmann-La Roche Ltd; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Biocartis; Advisory / Consultancy: Roche Diagnostics; Advisory / Consultancy: Boehringer Ingelheim. A. Vivancos: Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Sysmex; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Roche; Advisory / Consultancy: Guardant Health; Research grant / Funding (institution): Debio; Research grant / Funding (institution): Cellestia Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract